Published Online: Fri March 15, 2019
The treatment paradigm for HER2-positive breast cancer may be reshaped over the next several years, as head-to-head studies comparing new agents to the current standard of care begin to yield results, said Sara A. Hurvitz, MD.
Newer agents currently being evaluated in clinical trials include the oral tyrosine kinase inhibitors (TKIs) neratinib (Nerlynx) and tucatinib (ONT-380), the antibody–drug conjugate trastuzumab deruxtecan (DS-8201), and the monoclonal antibody margetuximab (MGAH22), said Hurvitz, director of Breast Cancer Clinical Research and an assistant professor of medicine at David Geffen School of Medicine at the University of California, Los Angeles.
During a presentation on current and new strategies in the treatment of advanced HER2-positive disease at the 36th Annual Miami Breast Conference® (MBCC), Hurvitz reviewed key data involving these drugs and other emerging agents.
“Head-to-head studies comparing some of these newer agents to standard of care are just beginning,” Hurvitz said in an interview in advance of her presentation. “So in anywhere between 5 and 10 years, 1 or 2 of these molecules may challenge the frontline or second-line standard that we have today, if their benefits and toxicity profile look better than our standard therapy.”
Read the full article here: https://www.targetedonc.com/news/novel-agents-may-challenge-standard-therapy-in-advanced-her2-breast-cancer